← Back to Dashboard

Paxlovid

3CL protease inhibitor + CYP3A4-inhibitor pharmacokinetic booster

Constituent drugs (2)

Nirmatrelvir

Could not render structureView on PubChem
3D not available

Ritonavir

Could not render structureView on PubChem
No structure available on PubChemSearch PubChem
PubChem CID 392622

Chemical Identifiers

ClinicalTrials.govPubMed

Clinical Development by Virus1

Approved (other)
Preclinical
Phase 2positive
Phase 3positive
Approved
Japan
Approval ref (kegg.jp) Approval ref (pmda.go.jp) PMDA approved 2022/2/10fixed-dose combination of Nirmatrelvir, Ritonavir.